Higher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia: A report from the Children’s Oncology Group

Posted by rob on April 1, 2011 under Uncategorized | Comments are off for this article

ConclusionsDaily oral imatinib at a dose of 340?mg/m2 is well tolerated in children. In addition, imatinib therapy is effective in inducing a high percent of hematologic, cytogenetic and molecular responses, comparable to adults with CML. (This study was registered at ClinicalTrials.gov under identifier NCT00030394.) Pediatr Blood Cancer © 2011 Wiley?Liss, Inc. (Source: Pediatric Blood and Cancer)
More